Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND

Phase 1positiveERNA-101Positive

AI Analysis

Summary

Ernexa Therapeutics reported positive safety results from three IND-enabling studies for ERNA-101, showing no adverse findings or cytokine release across dose levels tested. The company is advancing toward a planned Q4 2026 IND filing.

Clinical Trial Data

Phase

IND-enabling

Primary Endpoint

Met

Outcome Details

Repeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels tested, including no clinical pathology or histopathology findings; single-dose assessment showed no evidence of acute cytokine release

Importance:6/10

Sentiment:

0.85

toxicologysafetyIND-enabling studiesERNA-101preclinical

Related Companies

$ERNAW

Read the original article

Published by GlobeNewswire Clinical Studies on September 30, 2026 12:32 PM

Read Original